Carboplatin + Gemcitabine & Bladder cancer

Regulatory perspective:

In the context of Carboplatin + Gemcitabine & Bladder cancer, Carboplatin + Gemcitabine is a widely used first‑line regimen for cisplatin‑ineligible patients with locally advanced or metastatic Bladder cancer, but it does not have a specific, dedicated FDA or EMA “combination” approval for this indication in the way newer regimens (e.g., nivolumab + GC, EV + pembrolizumab) do. Instead, both agents are individually approved anticancer drugs, and the doublet is recommended in guidelines and described in product information and reviews as an accepted standard option

Clinical data:

The randomized clinical phase III trial, identified as NCT01993979 (POUT), demonstrated that…